References
- Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Can-dida species. Antimicrob Agents Chemother 199640:1948-1949.
- GeorgeD, Miniter P, Andriole VT. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996; 40: 86–91.
- Ghannoum MA, Okogbule-Wonodi I, Bhat N, Sanati H. Anti-fungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. J Chemother 1999; 11: 34–39.
- Marco F, Pfaller MA, Messer SA, Jones RN. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 1998; 36: 433–436.
- Girmenia C, LU7i G, Monaco M, Martino P. Use of voriconazole in treatment of S cedosporium apiospermum infection: case report. J Gun Microbiol 1998; 36: 1436–1438.
- Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazoleresistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12: 2227–2228.
- Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebralaspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97: 663–665.
- van't Hek LG, Verweij PE, Weemaes CM, van Dalen R, Yntema JB, Meis JF. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Grit Care Med 1998; 157: 1694–1696.
- Andriole VT, Miniter P, George D, Kordick D, Patterson TF. Animalmodels:Their usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Clin Infect Dis 1992; 14 \((Suppl. 1)): S134—S138.
- Stevens DA. Animal models in the evaluation of antifungal drug s.J Mycol Med 1996; 6: 7–10.
- Patterson B, Coates P. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: dispo-sition in man. Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washing-ton DC: American Society of Microbiology, 1995: Abstract F78.
- Jezquel S, Clark M, Cole S, Evans K, Wastall P. UK-109,496, a novel wide-spectrum triazole derivative for the treatment of fungal infections: preclinical pharmacokinetics. Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, 1995: Abstract F76.
- Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997; 41: 13–16.
- Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40–79.
- Chan WK, Nguyen LT, Miller VP, Harris RZ. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998; 62: L135–142.
- Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Safety 1998; 18:251–272.
- Sugar AM. Use of amphotericin B with azole antifungal drugs: What are we doing? Antimicrob Agents Chemother 1995; 39: 1907-1912.
- He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998; 11: 252–259. 0 2000 1SHAM, Medical Mycology, 38, 209-212